Currently out of the existing stock ratings of Joshua Schimmer, 250 are a BUY (90.91%), 25 are a HOLD (9.09%).

Joshua Schimmer

Work Performance Price Targets & Ratings Chart

Analyst Joshua Schimmer, currently employed at CANTOR FITZGERALD, carries an average stock price target met ratio of 62.2% that have a potential upside of 56.1% achieved within 397 days.

Joshua Schimmer’s has documented 758 price targets and ratings displayed on 61 stocks. The coverage is on Healthcare, Industrials, Technology, Energy, Consumer Defensive sectors.

Most recent stock forecast was given on NBIX, Neurocrine Biosciences at 30-Jul-2026.

Wall Street Analyst Joshua Schimmer

Analyst best performing recommendations are on TAL (TAL EDUCATION GROUP).
The best stock recommendation documented was for CRSP (CRISPR THERAPEUTICS AG) at 11/14/2016. The price target of $21 was fulfilled within 2 days with a profit of $3.4 (19.32%) receiving and performance score of 96.59.

Average potential price target upside

of $67.15 (91.71%) on BL (BLACKLINE).
of $65.63 (52.1%) on ASND (ASCENDIS PHARMA AS).
of $62.54 (21.92%) on BIIB (BIOGEN).

ALXN Alexion Pharmaceuticals BLU BELLUS Health DICE Dice Molecules Holdings LLC FDMT 4D Molecular Therapeutics HRTX Heron Therapeuti INSM Insmed IONS Ionis Pharmaceuticals MDGL Madrigal Pharmaceuticals REGN Regeneron Pharmaceuticals RGNX Regenxbio SPRO Spero Therapeutics VTYX Ventyx Biosciences CABA Cabaletta Bio ICVX Icosavax INBX Inhibrx ADMS Adamas Pharmaceuticals GOSS Gossamer Bio RNA Avidity Biosciences ZYME Zymeworks Common Stock AKRO Akero Therapeutics BBIO BridgeBio Pharma CRNX Crinetics Pharmaceuticals ERAS Erasca INCY yte KDNY Chinook Therapeutics KRYS Krystal Biotech ASND Ascendis Pharma AS PMVP Pmv Pharmaceuticals LBPH Longboard Pharmaceuticals MIRM Mirum Pharmaceuticals XENE Xenon Pharmaceuticals ALEC Alector JANX Janux Therapeutics CGON CG Oncology, Common stock SEPN Septerna, Common Stock SPRY ARS Pharmaceuticals ABBV AbbVie AXON Axon Enterprise CBAY Cymabay Therapeu CMPS Compass Pathways Plc DVAX Dynavax Technologies MITO Stealth BioTherapeutics Corp DNLI Denali Therapeutics RLYB Rallybio Corp NBIX Neurocrine Biosciences ALT Altimmune ARTV Artiva Biotherapeutics, Common Stock BL Blackline CGEM Cullinan Oncology LLC CRSP Crispr Therapeutics AG GHRS GH Research PLC LB L Brands NUVL Nuvalent QURE Uniqure NV RCKT Rocket Pharmaceuticals SU Suncor Energy TAL TAL Education Group TBPH Theravance Biopharma TGTX TG Therapeutics TRVI Trevi Therapeutics VYGR Voyager Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hartaj Singh (OPPENHEIMER)

Buy Since 28-Jul-2017

$205

$22.5 (12.33%)

5 years 4 months 3 days ago
(05-May-2021)

3/5 (60%)

$35.09 (20.65%)

938

Geoffrey Porges (LEERINK)

Hold Since 03-May-2021

$173

$-9.5 (-5.21%)

$156

5 years 4 months 5 days ago
(03-May-2021)

17/29 (58.62%)

$2.73 (1.60%)

650

Martin Auster (RAYMOND JAMES)

Hold Since 04-Feb-2021

$190

$7.5 (4.11%)

$190

5 years 4 months 13 days ago
(26-Apr-2021)

11/14 (78.57%)

$23 (13.77%)

420

Phil Nadeau (TD COWEN)

Buy Since 06-Sep-2019

$175

$-7.5 (-4.11%)

$165

5 years 7 months 4 days ago
(04-Feb-2021)

3/3 (100%)

$19.41 (12.48%)

397

Christopher James

Buy Since 17-Jul-2017

$166

$-16.5 (-9.04%)

$175

5 years 7 months 4 days ago
(04-Feb-2021)

32/33 (96.97%)

$10.41 (6.69%)

867

Show more analysts

Please expand the browser size to see the chart

Which stock is Joshua Schimmer most bullish on?

Potential upside of $59.87 has been obtained for NBIX (NEUROCRINE BIOSCIENCES)

Which stock is Joshua Schimmer most reserved on?

Potential downside of -$0 has been obtained for NUVL (NUVALENT)

What Year was the first public recommendation made by Joshua Schimmer?

On 2013